Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

Launched by ANHUI PROVINCIAL HOSPITAL · Jul 6, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with locally advanced esophageal cancer, specifically focusing on combining postoperative radiotherapy (radiation treatment after surgery) with immunotherapy (a treatment that helps your immune system fight cancer). The goal is to see if this combination can improve recovery and prevent the cancer from coming back after surgery. Previous studies have shown that immunotherapy can help patients live longer without their cancer returning, so researchers want to explore how it works alongside radiotherapy.

To participate in this trial, patients should be between 18 and 75 years old, have had surgery to remove their esophageal cancer (esophagectomy), and have a specific type of esophageal cancer called squamous cell carcinoma. They should also have had a sufficient number of lymph nodes removed during surgery for proper staging of the disease. Participants can expect close monitoring and support throughout the study, and they will need to provide consent to join. This trial is actively recruiting participants, and it's a chance to be part of research that could lead to better treatment options for esophageal cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18-75 years old.
• • After esophagectomy.
• • Confirmation of squamous cell carcinoma by pathological examination.
• • Pathological staging of pIIb-IVa.
• • Over 12 lymph nodes dissected during surgery.
• • ECOG 0-1.
• • Signature of inform consent by patients
• Exclusion Criteria:
• • Younger than 18 years old or older than 75 years old.
• • Without esophagectomy.
• • Non-squamous cell carcinoma.
• • Pathological staging of pI, IIa, IVb.
• • Less than 12 lymph nodes dissected during surgery.
• • ECOG 2-3 g. no signature of inform consent.